## Abraham Fisher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10166741/publications.pdf

Version: 2024-02-01

567281 996975 1,403 15 15 15 citations h-index g-index papers 15 15 15 1385 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Reimagining cholinergic therapy for Alzheimer's disease. Brain, 2022, 145, 2250-2275.	7.6	50
2	AF710B, an M1/sigmaâ€1 receptor agonist with longâ€lasting diseaseâ€modifying properties in a transgenic rat model of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 811-823.	0.8	39
3	Acute Effects of Muscarinic M1 Receptor Modulation on AÎ <sup>2</sup> PP Metabolism andÂAmyloid-Î <sup>2</sup> Levels in vivo: AÂMicrodialysis Study. Journal of Alzheimer's Disease, 2015, 46, 971-982.	2.6	17
4	Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. Journal of Neurochemistry, 2012, 120, 22-33.	3.9	115
5	ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/Î $\mu$ . Molecular and Cellular Neurosciences, 2011, 47, 223-232.	2.2	32
6	Cholinergic Treatments with Emphasis on M1 Muscarinic Agonists as Potential Disease-Modifying Agents for Alzheimer's Disease. Neurotherapeutics, 2008, 5, 433-442.	4.4	130
7	Isoform-specific contribution of protein kinase C to prion processing. Molecular and Cellular Neurosciences, 2008, 39, 400-410.	2.2	20
8	M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. Neuron, 2006, 49, 671-682.	8.1	383
9	M1 muscarinic receptor activation protects neurons from $\hat{l}^2$ -amyloid toxicity. A role for Wnt signaling pathway. Neurobiology of Disease, 2004, 17, 337-348.	4.4	71
10	AF150(S) and AF267B. Journal of Molecular Neuroscience, 2002, 19, 145-153.	2.3	80
11	Use of Muscarinic Agonists in the Treatment of SjĶgren's Syndrome. Clinical Immunology, 2001, 101, 249-263.	3.2	91
12	Reduction of cerebrospinal fluid amyloid $\hat{l}^2$ after systemic administration of M1 muscarinic agonists. Brain Research, 2001, 905, 220-223.	2.2	70
13	Therapeutic Strategies in Alzheimer's Disease: Ml Muscarinic Agonists. The Japanese Journal of Pharmacology, 2000, 84, 101-112.	1.2	69
14	Mitogenâ€Activated Protein Kinaseâ€Dependent and Protein Kinase Câ€Dependent Pathways Link the m1 Muscarinic Receptor to βâ€Amyloid Precursor Protein Secretion. Journal of Neurochemistry, 1998, 71, 2094-2103.	3.9	111
15	Activation of m <sub>1</sub> Muscarinic Acetylcholine Receptor Regulates Ï,, Phosphorylation in Transfected PC12 Cells. Journal of Neurochemistry, 1996, 66, 877-880.	3.9	125